12-month results with small-aperture IOL providing patients with an extended range of vision
Minimally invasive surgical solutions for presbyopia
Minimally invasive surgical solutions for presbyopiaPresbyopia, an age-related loss of accommodative amplitude of the eye resulting in near and intermediate vision deficits, begins to affect most people once they reach their early 40s.
Intracorneal inlays for the correction of presbyopia and low hyperopiaNew alloplastic materials are being used as intracorneal inlays to offer predictable and safe refractive surgical correction of presbyopia and low hyperopia. The major problem with such inlays is the wound-healing response following their insertion; however, they can easily be removed.
New correction option for presbyopes
New correction option for presbyopesAt present we are limited with our ability to treat presbyopes. Sure, we have progressives and multifocal contact lenses; however, from a surgical standpoint, monovision corneal refractive surgery is limited, and clear lens extraction is often extreme for emmetropes.
FDA approves AcuFocus corneal inlayThe FDA has approved AcuFocus’ corneal inlay product (KAMRA inlay.) The device is indicated to improve near vision by extending depth of focus in patients with presbyopia who have emmetropic refractions (+0.50 to –0.75 D).
Quantel, AcuFocus receive CE approvalsOphthalmology technology from Quantel Medical and AcuFocus recently received CE Mark approval.
Two-stage, well-tolerated procedure for inlay ensures refractive stabilityThe optimal time of implantation of a corneal inlay (Kamra, AcuFocus) to correct presbyopia in ametropic presbyopic patients seems to be 1 week after traditional LASIK in a planned two-stage KAMRA procedure.
Replacement of dysfunctional lens may pose multiple benefitsDysfunctional lens replacement may be a better option in certain cases for patients with dysfunctional lens syndrome who initially seek LASIK correction. With the availability of advanced diagnostic equipment, surgeons can now identify candidates and recommend this solution.
FDA: Kamra inlay benefits outweigh risksFollowing deliberations, the FDA’s ophthalmic devices advisory panel has determined that the benefits of AcuFocus’ Kamra inlay outweigh the risks for patients suffering vision loss as a result of presbyopia.
FDA advisory panel says benefits of Kamra inlay outweigh risksThe U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel recently determined that the benefits of AcuFocus’ Kamra inlay outweigh the risks for presbyopic patients.